Business Context and Reporting Period
Company: Ainos, Inc. (AIMD)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Ainos is a dual-platform company focused on commercializing "AI Nose," an AI-based scent digitization platform for industrial and healthcare applications, and developing "VELDONA," a low-dose oral interferon therapeutic platform. The company operates as a smaller reporting company with a significant presence in Taiwan for R&D and manufacturing.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenues | $124,157 | $20,729 |
| Gross Profit | $102,911 | $(31,866) |
| Operating Loss | $(13,990,408) | $(13,841,204) |
| Net Loss | $(14,771,012) | $(14,863,161) |
| Cash and Cash Equivalents (End of Period) | $417,353 | $3,892,919 |
| Accumulated Deficit | $(67,520,328) | $(52,749,316) |
| Convertible Notes Payable (Non-current) | $11,000,000 | $9,000,000 |
Note: Revenue growth in 2025 was driven by the initial commercialization of AI Nose ($123,360), offset by a decline in pet supplement sales.
Material Changes vs. Prior Period
- Revenue Mix Shift: The company transitioned from relying on pet supplements and discontinued COVID-19 test kits to generating revenue from AI Nose industrial deployments. Total revenue increased 499% year-over-year.
- Liquidity Decline: Cash and cash equivalents decreased by approximately $3.48 million (89%) to $417,353, primarily due to operating losses and reduced financing inflows compared to 2024.
- Debt Structure: The company repaid several convertible notes (including the Lee Note and Lind Note) but maintained significant non-current convertible debt ($11 million) primarily from related parties (ASE Test, Inc.).
- Stock Splits: A 1-for-5 reverse stock split was effectuated on June 30, 2025, to comply with Nasdaq listing rules.
Guidance, Outlook, and Risks
Management Commentary and Outlook
Management is prioritizing the scaling of the AI Nose platform through partner-led industrial deployments (semiconductor, robotics) and maintaining capital efficiency in healthcare programs. The company expects to continue incurring operating losses as it advances product pipelines. Future funding is anticipated to come from existing cash, revenues, and additional equity or debt financing.
Going Concern Warning
The filing explicitly states that substantial doubt exists about the company's ability to continue as a going concern for at least one year from the issuance date. This is due to recurring losses, an accumulated deficit of $67.5 million, and a reliance on future financing which is not guaranteed.
Key Risks
- Capital Adequacy: The company requires additional capital to fund operations and product development. Failure to secure funding could force a reduction in R&D or cessation of operations.
- Commercialization Uncertainty: AI Nose is in early commercialization; there is no assurance of market acceptance or recurring revenue.
- Related Party Dependence: Significant reliance on related parties (TCNT, ASE Test) for manufacturing, R&D, and debt financing.
- Regulatory Hurdles: VELDONA and POCT products require regulatory approvals (FDA, TFDA) which are uncertain and costly.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $417k cash balance against current burn rates and the timeline for the next financing round.
- Related Party Transactions: Review the terms of the $11M convertible notes and manufacturing agreements with ASE Test and TCNT to assess potential conflicts of interest or unfavorable terms.
- Revenue Recognition: Confirm the sustainability of the $2.1M multi-year subscription contract with ASE Technology Holding and the timing of revenue recognition.
- Going Concern Status: Assess the likelihood of securing the necessary equity or debt financing to avoid insolvency within the next 12 months.
- Intellectual Property: Verify the status of the patent license agreement with TCNT and the valuation of intangible assets ($19.2M net) given the impairment testing performed.